Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Business Wire India If Approved, HYQVIA Would Offer an up to Once-Monthly Facilitated Subcutaneous At-Home or In-Office Treatment Option Positive Opinion Based on Phase 3 ADVANCE-CIDP 1 Study, Which Met…